Lundbeck has announced plans to to investigate Lu AA21004 for the treatment of depression in patients and will enrol the first patient in a 400 patient Phase II study by the end of third quarter 2006. The decision is based on positive pre-clinical results as well as positive
conclusion of the Phase I trials in healthy individuals.
Lu AA21004 is
the most advanced project in Lundbeck within a new chemical class, the bis-aryl-sulphanyl
amines. The pharmacology of these projects is markedly different from any currently
marketed antidepressants.
Compared with currently approved antidepressants
preclinical models have demonstrated Lu AA21004 to address important unmet needs
for patients on both fast onset of effect and increased efficacy.
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Complaint Handling, Process Controls Lacking at Battery Maker Alpha Source
Complaint records lacked adequate documentation of the root cause or corrective actions taken.
FDA Approves Treatment for Thrombocytopenia
Both dosage levels of Doptelet led to a higher proportion of patients with increased platelet counts.